REG - Belluscura PLC - Launch of Next Gen X-PLOR Oxygen Concentrator

BelluscuraAnnouncement

27/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220627:nRSa2048Qa&default-theme=true

RNS Number : 2048Q  Belluscura PLC  27 June 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura PLC

("Belluscura" or the "Company")

 

Launch of Next Generation X-PLOR Portable Oxygen Concentrator

 

The latest product in the ground-breaking X-PLOR range will be the first
portable concentrator with a mobile app that will connect with phones,
tablets, pulse oximeters and wearables

 

LONDON, U.K. AND PLANO, TX, U.S. (27 June 2022). Belluscura plc (AIM: BELL), a
leading medical device developer focused on lightweight and portable oxygen
enrichment technology, announces the launch of its Bluetooth® enabled, next
generation X-PLOR® portable oxygen concentrator (previously described as the
X-PLOR CX).

 

The next generation X-PLOR provides more oxygen by weight than any portable
oxygen concentrator in its class and with its new Nomad Health™ App,
patients can connect other Bluetooth® devices such as their iPhone® or
Android phone, Nonin® or Masimo® pulse oximeters, and Fitbit® wearables.
Patients will be able to track their oxygen usage, breathing rates, blood
oxygen saturation levels, heart rate, sleep and other important biometric and
environmental data. The patient can then share this important healthcare data
with their provider.

 

With the launch of the next generation X-PLOR, Belluscura continues to add
more sizable distributors and durable medical equipment providers to its
distribution network.

 

Robert Rauker, CEO of Belluscura plc, said: "I am very excited about the
launch of the next generation X-PLOR with the Nomad Health App. Our goal is to
not only provide cutting edge medical devices, but to also improve patient
outcomes with every new product we launch. We believe putting more health and
environmental information in the hands of our patients will result in greatly
improved long-term patient outcomes."

 

Patrick J Strollo, Jr, MD Pulmonologist and Non-executive Director of
Belluscura, said: ""Telemonitoring of home oxygen therapy is the present not
the future. The ability to connect to wearable biometric devices will help
improve patient care."

 

 

For further information please contact:

 

 Belluscura plc                                    www.belluscura.com (http://www.belluscura.com)
 Robert Rauker, Chief Executive Officer            via Walbrook PR
 Anthony Dyer, Chief Financial Officer

 SPARK Advisory Partners Limited (NOMAD)           Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Dowgate Capital Limited (Broker)                  Tel: +44 (0)20 3903 7715
 James Serjeant / Nicholas Chambers

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

 

About Belluscura plc (www.belluscura.com (http://www.belluscura.com) )

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAKKKAFXAEFA